A Pilot Study of Imetelstat given Intravenously on Day 1 and 8 of a 21 Day Scheudule Alone and With Standard 13Cis-Retinoic Acid in Children with Recurrent and/or Refractory Neuroblastoma
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 28 Mar 2016
At a glance
- Drugs Imetelstat (Primary) ; Isotretinoin
- Indications Neuroblastoma
- Focus Therapeutic Use
- 01 Nov 2013 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 02 Aug 2013 Planned number of patients (18) added as reported by ClinicalTrials.gov.
- 02 Aug 2013 Planned end date (1 Apr 2016) added as reported by ClinicalTrials.gov.